200 related articles for article (PubMed ID: 29461635)
1. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
Teot LA; Schneider M; Thorner AR; Tian J; Chi YY; Ducar M; Lin L; Wlodarski M; Grier HE; Fletcher CDM; van Hummelen P; Skapek SX; Hawkins DS; Wagers AJ; Rodriguez-Galindo C; Hettmer S
Cancer; 2018 May; 124(9):1973-1981. PubMed ID: 29461635
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.
Agaram NP; Huang SC; Tap WD; Wexler LH; Antonescu CR
Genes Chromosomes Cancer; 2022 Mar; 61(3):131-137. PubMed ID: 34755412
[TBL] [Abstract][Full Text] [Related]
3. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
4. Uncovering metabolism in rhabdomyosarcoma.
Monti E; Fanzani A
Cell Cycle; 2016; 15(2):184-95. PubMed ID: 26209235
[TBL] [Abstract][Full Text] [Related]
5. SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma.
Karanian M; Pissaloux D; Gomez-Brouchet A; Chevenet C; Le Loarer F; Fernandez C; Minard V; Corradini N; Castex MP; Duc-Gallet A; Blay JY; Tirode F
Am J Surg Pathol; 2020 May; 44(5):607-616. PubMed ID: 32187044
[TBL] [Abstract][Full Text] [Related]
6. Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children.
Kazanowska B; Reich A; Stegmaier S; Békássy AN; Leuschner I; Chybicka A; Koscielniak E
Fetal Pediatr Pathol; 2007; 26(1):17-31. PubMed ID: 17613043
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
8. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
[TBL] [Abstract][Full Text] [Related]
10. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
[TBL] [Abstract][Full Text] [Related]
11. Clonality and evolutionary history of rhabdomyosarcoma.
Chen L; Shern JF; Wei JS; Yohe ME; Song YK; Hurd L; Liao H; Catchpoole D; Skapek SX; Barr FG; Hawkins DS; Khan J
PLoS Genet; 2015 Mar; 11(3):e1005075. PubMed ID: 25768946
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.
Pressey JG; Anderson JR; Crossman DK; Lynch JC; Barr FG
Pediatr Blood Cancer; 2011 Dec; 57(6):930-8. PubMed ID: 21618411
[TBL] [Abstract][Full Text] [Related]
13. Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.
Kashi VP; Hatley ME; Galindo RL
Nat Rev Cancer; 2015 Jul; 15(7):426-39. PubMed ID: 26105539
[TBL] [Abstract][Full Text] [Related]
14. Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.
Casey DL; Wexler LH; Pitter KL; Samstein RM; Slotkin EK; Wolden SL
Clin Cancer Res; 2020 Mar; 26(5):1135-1140. PubMed ID: 31699828
[TBL] [Abstract][Full Text] [Related]
15. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma.
Harel M; Ferrer FA; Shapiro LH; Makari JH
Urol Oncol; 2016 Feb; 34(2):103-15. PubMed ID: 26519985
[TBL] [Abstract][Full Text] [Related]
16. Signaling pathways in Rhabdomyosarcoma invasion and metastasis.
Ramadan F; Fahs A; Ghayad SE; Saab R
Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Shern JF; Chen L; Chmielecki J; Wei JS; Patidar R; Rosenberg M; Ambrogio L; Auclair D; Wang J; Song YK; Tolman C; Hurd L; Liao H; Zhang S; Bogen D; Brohl AS; Sindiri S; Catchpoole D; Badgett T; Getz G; Mora J; Anderson JR; Skapek SX; Barr FG; Meyerson M; Hawkins DS; Khan J
Cancer Discov; 2014 Feb; 4(2):216-31. PubMed ID: 24436047
[TBL] [Abstract][Full Text] [Related]
18. PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells.
Yoshida H; Miyachi M; Sakamoto K; Ouchi K; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Imamura T; Iehara T; Kakazu N; Hojo H; Hosoi H
Oncogene; 2014 Dec; 33(49):5601-8. PubMed ID: 24213582
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.
Davicioni E; Anderson JR; Buckley JD; Meyer WH; Triche TJ
J Clin Oncol; 2010 Mar; 28(7):1240-6. PubMed ID: 20124188
[TBL] [Abstract][Full Text] [Related]
20. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
